Huggins Melissa E, Bhatia Narender N, Ostergard Donald R
University of California, Irvine College of Medicine, Irvine, California, USA.
Curr Opin Obstet Gynecol. 2003 Oct;15(5):419-27. doi: 10.1097/00001703-200310000-00011.
Urinary incontinence is an under-reported epidemic with profound effects on quality of life. With recent pharmacologic advances, the belief that incontinence is an inevitable part of aging should be abandoned. Because many patients are unaware of curative options, they fail to report their symptoms and increase their risk of developing associated comorbid disease. Failure to diagnose and treat this disease in a timely manner increases society's economic burden associated with incontinence.
Pharmacologic treatment of urge incontinence previously had limited treatment success because efficacious drugs were poorly tolerated, resulting in low patient compliance. Tolerance continues to be improved due to innovative new drugs and alternative delivery systems. While previous pharmacologic management of mild stress incontinence consisted of off-label agents with limited effectiveness, newly introduced drug therapy adds a viable, nonsurgical option for women with stress incontinence.
The goal of this review is to update the clinician on the efficacy and tolerability of established and investigational pharmacologic modalities of therapy.
尿失禁是一种报告不足的流行病，对生活质量有深远影响。随着近期药理学的进展，应摒弃失禁是衰老不可避免的一部分这一观念。由于许多患者不知道有治愈方法，他们未报告症状，从而增加了患相关合并症的风险。未能及时诊断和治疗这种疾病增加了社会与尿失禁相关的经济负担。
过去，急迫性尿失禁的药物治疗成功率有限，因为有效药物耐受性差，导致患者依从性低。由于创新的新药和替代给药系统，耐受性持续得到改善。虽然过去轻度压力性尿失禁的药物治疗采用疗效有限的非适应证药物，但新引入的药物疗法为压力性尿失禁女性提供了一种可行的非手术选择。
本综述的目的是向临床医生介绍已确立的和正在研究的药物治疗方法的疗效和耐受性。
